Many investors have asked for some of the best investment opportunities based on the DEA’s decision to make CBD a Schedule I substance and we have an answer for you…
Short AXIM Biotechnologies, Inc. (AXIM)
First, the shares are up more than 2,000% off its November lows and the company’s fundamental story has not changed! I mean…come on…this is not 2014. Investors need to focus on good companies and not be left holding dogs like AXIM when the shares come crashing down.
That is right. AXIM will come crashing down.
The reason why AXIM will lose more than 90% of its current value is simple…valuation! Did you know that at current levels, AXIM is worth 200% more than Zynerba Pharmaceuticals (ZYNE), a Nasdaq traded company that has real products in real FDA clinical and pre-clinical trials.
Do you want to own a stock that Medical Marijuana (MJNA) has a significant stake in. Although MJNA has good awareness due to it being the first publicly traded company, its financial structure might be the most shareholder unfriendly structure in the cannabis universe. What I am telling you right is the best Christmas gift ever! Take my advice… Sell AXIM and then use your proceeds to short it.
DISCLAIMER: This is a trade opinion based on an CBD restriction catalyst. All ideas are opinions and we have zero positions short or long in companies mentioned above.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | email@example.com